Evgeny Kulesskiy

List of Publications by Year
in descending order

29	1,695	18	26
papers	citations	h-index	g-index
		489802	620720

33	33	33	3762
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.	7.7	334
2	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 2014, 4, 5193.	1.6	243
3	Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. Journal of Cell Biology, 2011, 192, 153-169.	2.3	164
4	Methods for High-throughput Drug Combination Screening and Synergy Scoring. Methods in Molecular Biology, 2018, 1711, 351-398.	0.4	140
5	PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine, 2018, 10, .	5.8	116
6	N-syndecan deficiency impairs neural migration in brain. Journal of Cell Biology, 2006, 174, 569-580.	2.3	114
7	Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages. Molecular and Cellular Proteomics, 2016, 15, 3203-3219.	2.5	66
8	Antifungal Application of Nonantifungal Drugs. Antimicrobial Agents and Chemotherapy, 2014, 58, 1055-1062.	1.4	65
9	Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naÃ¯ve glioblastoma. BMC Cancer, 2019, 19, 628.	1.1	55
10	Identification and Tracking of Antiviral Drug Combinations. Viruses, 2020, 12, 1178.	1.5	48
11	Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. Journal of Biological Chemistry, 2020, 295, 4194-4211.	1.6	48
12	HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix. Scientific Reports, 2016, 6, 33916.	1.6	43
13	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses, 2017, 9, 271.	1.5	39
14	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular Cancer Therapeutics, 2018, 17, 2060-2071.	1.9	33
15	Transmembrane Prostatic Acid Phosphatase (TMPAP) Interacts with Snapin and Deficient Mice Develop Prostate Adenocarcinoma. PLoS ONE, 2013, 8, e73072.	1.1	28
16	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecologic Oncology, 2017, 144, 621-630.	0.6	26
17	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. Journal of the Association for Laboratory Automation, 2016, 21, 27-36.	2.8	22
18	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. Biomolecules, 2020, 10, 1365.	1.8	22

#	Article	IF	Citations
19	Feasibility study of using highâ€throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Clinical and Translational Medicine, 2019, 8, 33.	1.7	20
20	HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiation. Scientific Reports, 2016, 6, 32960.	1.6	14
21	Anagrelide for Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 1676-1687.	3.2	14
22	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. Cancers, 2020, 12, 1694.	1.7	13
23	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. Briefings in Bioinformatics, 2022, 23, .	3.2	7
24	A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland. Synergy, 2014, 1, 78.	1.1	4
25	Ligand-induced dimerization of syndecan-3 at the cell surface. Advances in Bioscience and Biotechnology (Print), 2013, 04, 36-44.	0.3	1
26	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. Blood, 2012, 120, 288-288.	0.6	1
27	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487.	0.6	0
28	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	0.6	0
29	TBIO-18. ESTABLISHING A PIPELINE FOR INDIVIDUALIZED TREATMENT OPTIONS FOR PEDIATRIC BRAIN CANCER. Neuro-Oncology, 2020, 22, iii470-iii470.	0.6	0